NEW YORK — Freenome said on Wednesday that it has partnered with German medical technology firm Siemens Healthineers on the identification of blood-based biomarkers for breast cancer detection.
South San Francisco-based Freenome said that the partners will use epigenetic, proteomic, genomic, immunologic, and other types of data to identify blood markers that can complement current imaging technologies for the early diagnosis of the disease.
"Siemens Healthineers is an established leader in the development of imaging and diagnostic technologies, especially in breast cancer screening with more recent improvements leveraging 3D mammograms or digital breast tomosynthesis," Freenome CEO Mike Nolan said in a statement. "This collaboration will give us even more insights on how we can incorporate unique data types to address the unmet medical needs for one of the most common cancers."
Freenome, which uses artificial intelligence to develop multiomic cancer tests, recently presented data highlighting the use of its technology in pancreatic cancer.